The aim of immunotherapy - also commonly referred to as antibody therapy - (as with any maintenance therapy) is to keep your child in remission and keep the cancer away.

It helps the body’s own defences to turn against the neuroblastoma cells using antibodies.

This should hopefully stop the cancer from returning as the body will learn to recognise and kill the cells.

After immunotherapy, some families look towards clinical trials to do even more to try and stop a relapse. 

Immunotherapy is given into the bloodstream and lasts for six months.


The antibody used for neuroblastoma is called anti-GD2 and researchers had been testing a type called dinutuximab beta. GD2 is the substance found on the surface of many neuroblastoma cells.

Solving Kids’ Cancer worked alongside a range of other charities to push for the outcome of NICE recommending the life-saving drug for NHS use in England and Wales. Read our statement here.